Onyx Pharmaceuticals Providing 340B Refunds on Kyprolis

by Admin | September 9, 2013 3:48 pm

September 9, 2013—Biopharmaceutical manufacturer Onyx, which is being purchased by biotech giant Amgen for $10.4 billion, has announced that 340B covered entities that bought its injectable oncology medication Kyprolis during the first quarter of 2013 might be eligible for refunds for overcharges. 

You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register[1].    Already registered? Click here to login[2]. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)

Endnotes:
  1. Click here to register: https://secure.340bhealth.org/340Binformed/Subscribe.aspx
  2. Click here to login: http://340binformed.org/reader-login/

Source URL: https://340binformed.org/2013/09/onyx-pharmaceuticals-providing-340b-refunds-on-kyprolis/

Copyright ©2026 340binformed.org unless otherwise noted.